|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Herszényi L and Tulassay Z: Epidemiology
of gastrointestinal and liver tumors. Eur Rev Med Pharmacol Sci.
14:249–258. 2010.PubMed/NCBI
|
|
3
|
Brenner H, Rothenbacher D and Arndt V:
Epidemiology of stomach cancer. Methods Mol Biol. 472:467–477.
2009. View Article : Google Scholar
|
|
4
|
Kusano T, Shiraishi N, Shiroshita H, Etoh
T, Inomata M and Kitano S: Poor prognosis of advanced gastric
cancer with metastatic suprapancreatic lymph nodes. Ann Surg Oncol.
20:2290–2295. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Murphy PM, Baggiolini M, Charo IF, Hébert
CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ and Power CA:
International Union of Pharmacology. XXII Nomenclature for
chemokine receptors. Pharmacol Rev. 52:145–176. 2000.PubMed/NCBI
|
|
6
|
Zlotnik A and Yoshie O: Chemokines: A new
classification system and their role in immunity. Immunity.
12:121–127. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Balkwill F: Cancer and the chemokine
network. Nat Rev Cancer. 4:540–550. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wells TN, Lusti-Narasimhan M, Chung CW,
Cooke R, Power CA, Peitsch MC and Proudfoot AE: The molecular basis
of selectivity between CC and CXC chemokines: The possibility of
chemokine antagonists as anti-inflammatory agents. Ann NY Acad Sci.
796:1 Cytokines. 245–256. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vandercappellen J, Van Damme J and Struyf
S: The role of CXC chemokines and their receptors in cancer. Cancer
Lett. 267:226–244. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh S, Nannuru KC, Sadanandam A, Varney
ML and Singh RK: CXCR1 and CXCR2 enhances human melanoma
tumourigenesis, growth and invasion. Br J Cancer. 100:1638–1646.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ginestier C, Liu S, Diebel ME, Korkaya H,
Luo M, Brown M, Wicinski J, Cabaud O, Charafe-Jauffret E, Birnbaum
D, et al: CXCR1 blockade selectively targets human breast cancer
stem cells in vitro and in xenografts. J Clin Invest. 120:485–497.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Y, Shi M, Yu GZ, Qin XR, Jin G, Chen
P and Zhu MH: Interleukin-8, a promising predictor for prognosis of
pancreatic cancer. World J Gastroenterol. 18:1123–1129. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li A, Varney ML and Singh RK: Expression
of interleukin 8 and its receptors in human colon carcinoma cells
with different metastatic potentials. Clin Cancer Res. 7:3298–3304.
2001.PubMed/NCBI
|
|
15
|
Yang G, Rosen DG, Liu G, Yang F, Guo X,
Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, et al: CXCR2
promotes ovarian cancer growth through dysregulated cell cycle,
diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res.
16:3875–3886. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leonard DA, Merhige ME, Williams BA and
Greene RS: Elevated expression of the interleukin-8 receptors CXCR1
and CXCR2 in peripheral blood cells in obstructive coronary artery
disease. Coron Artery Dis. 22:491–496. 2011.PubMed/NCBI
|
|
17
|
Singh S, Wu S, Varney M, Singh AP and
Singh RK: CXCR1 and CXCR2 silencing modulates CXCL8-dependent
endothelial cell proliferation, migration and capillary-like
structure formation. Microvasc Res. 82:318–325. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang JP, Hu WM, Wang KS, Yu J, Luo BH, Wu
C, Chen ZH, Luo GQ, Liu YW, Liu QL, et al: Expression of C-X-C
chemokine receptor types 1/2 in patients with gastric carcinoma:
Clinicopathological correlations and significance. Oncol Lett.
5:574–582. 2013.PubMed/NCBI
|
|
19
|
Park SH, Das BB, Casagrande F, Tian Y,
Nothnagel HJ, Chu M, Kiefer H, Maier K, De Angelis AA, Marassi FM,
et al: Structure of the chemokine receptor CXCR1 in phospholipid
bilayers. Nature. 491:779–783. 2012.PubMed/NCBI
|
|
20
|
Jackson AL, Bartz SR, Schelter J,
Kobayashi SV, Burchard J, Mao M, Li B, Cavet G and Linsley PS:
Expression profiling reveals off-target gene regulation by RNAi.
Nat Biotechnol. 21:635–637. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fedorov Y, Anderson EM, Birmingham A,
Reynolds A, Karpilow J, Robinson K, Leake D, Marshall WS and
Khvorova A: Off-target effects by siRNA can induce toxic phenotype.
RNA. 12:1188–1196. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Z, Wang Y, Dong S, Ge C, Xiao Y, Li R,
Ma X, Xue Y, Zhang Q, Lv J, et al: Association of CXCR1 and 2
expressions with gastric cancer metastasis in ex vivo and tumor
cell invasion in vitro. Cytokine. 69:6–13. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Almhanna K, Strosberg J and Malafa M:
Targeting AKT protein kinase in gastric cancer. Anticancer Res.
31:4387–4392. 2011.PubMed/NCBI
|
|
24
|
Sasaki T and Kuniyasu H: Significance of
AKT in gastric cancer (Review). Int J Oncol. 45:2187–2192.
2014.PubMed/NCBI
|
|
25
|
Zhang Y, Wang L, Zhang M, Jin M, Bai C and
Wang X: Potential mechanism of interleukin-8 production from lung
cancer cells: An involvement of EGF-EGFR-PI3K-Akt-Erk pathway. J
Cell Physiol. 227:35–43. 2012. View Article : Google Scholar
|
|
26
|
Knall C, Worthen GS and Johnson GL:
Interleukin 8-stimulated phosphatidylinositol-3-kinase activity
regulates the migration of human neutrophils independent of
extracellular signal-regulated kinase and p38 mitogen-activated
protein kinases. Proc Natl Acad Sci USA. 94:3052–3057. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Correia C, Lee SH, Meng XW, Vincelette ND,
Knorr KL, Ding H, Nowakowski GS, Dai H and Kaufmann SH: Emerging
understanding of Bcl-2 biology: Implications for neoplastic
progression and treatment. Biochim Biophys Acta. 1853:1658–1671.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu
W, Yang Y and Chen G: βKlotho suppresses tumor growth in
hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1
signaling pathway. PLoS One. 8:e556152013. View Article : Google Scholar
|
|
29
|
Tsai HL, Yeh YS, Chang YT, Yang IP, Lin
CH, Kuo CH, Juo SH and Wang JY: Co-existence of cyclin D1 and
vascular endothe-lial growth factor protein expression is a poor
prognostic factor for UICC stage I-III colorectal cancer patients
after curative resection. J Surg Oncol. 107:148–154. 2013.
View Article : Google Scholar
|
|
30
|
Venkatakrishnan G, Salgia R and Groopman
JE: Chemokine receptors CXCR-1/2 activate mitogen-activated protein
kinase via the epidermal growth factor receptor in ovarian cancer
cells. J Biol Chem. 275:6868–6875. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luppi F, Longo AM, de Boer WI, Rabe KF and
Hiemstra PS: Interleukin-8 stimulates cell proliferation in
non-small cell lung cancer through epidermal growth factor receptor
transactivation. Lung Cancer. 56:25–33. 2007. View Article : Google Scholar
|
|
32
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Comparative effects of EGCG, green tea and a
nutrient mixture on the patterns of MMP-2 and MMP-9 expression in
cancer cell lines. Oncol Rep. 24:747–757. 2010.PubMed/NCBI
|
|
33
|
Roomi MW, Monterrey JC, Kalinovsky T, Rath
M and Niedzwiecki A: Patterns of MMP-2 and MMP-9 expression in
human cancer cell lines. Oncol Rep. 21:1323–1333. 2009.PubMed/NCBI
|
|
34
|
Sancéau J, Truchet S and Bauvois B: Matrix
metalloproteinase-9 silencing by RNA interference triggers the
migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem.
278:36537–36546. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bergers G, Brekken R, McMahon G, Vu TH,
Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, et al:
Matrix metalloproteinase-9 triggers the angiogenic switch during
carcinogenesis. Nat Cell Biol. 2:737–744. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu X and Chu KM: E-cadherin and gastric
cancer: Cause, consequence, and applications. Biomed Res Int.
2014:6373082014.PubMed/NCBI
|
|
37
|
Carneiro P, Figueiredo J, Bordeira-Carriço
R, Fernandes MS, Carvalho J, Oliveira C and Seruca R: Therapeutic
targets associated to E-cadherin dysfunction in gastric cancer.
Expert Opin Ther Targets. 17:1187–1201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kitadai Y: Cancer-stromal cell interaction
and tumor angiogenesis in gastric cancer. Cancer Microenviron.
3:109–116. 2010. View Article : Google Scholar
|
|
39
|
Bădescu A, Georgescu CV, Vere CC, Crăiţoiu
S and Grigore D: Correlations between Her2 oncoprotein, VEGF
expression, MVD and clinicopathological parameters in gastric
cancer. Rom J Morphol Embryol. 53:997–1005. 2012.
|
